🧬

Immunology

Therapies for autoimmune and inflammatory diseases, including biologics and small molecules targeting immune pathways.

Companies
0
Pipeline Drugs
669
Key People
1024

Immunology Pipeline (669 drugs)

Approved: 154Commercial: 126Phase 3: 62Phase 2: 46Phase 1: 37Pre-clinical: 33Phase 1/2: 24Approved/Commercial: 23Preclinical: 23Phase 2/3: 11Early Phase: 9Research-Use Only: 9Pre-clinical (Tool): 8Phase 1b: 7Phase 2b: 7Research: 5Clinical: 4Various: 4Clinical Development: 3Development: 3Preclinical/Phase 1: 3Discovery: 3Commercial (RUO): 3IND-Enabling: 2Phase 2b/3: 2Phase (Early Clinical): 2Commercial/Approved: 2Discovery/Preclinical: 2Lead Optimization: 2Not Disclosed: 2Phase 2a: 2Preclinical to Phase 1/2: 2Phase 3-ready: 2Acquisition: 1Phase 1-3: 1Multiple Phases: 1Filed: 1Operational: 1R&D: 1Phase 1a/1b: 1Phase 1a: 1Emergency Use Authorization (Past): 1Discovery/Pre-clinical: 1Discovery to Preclinical: 1Research/Pre-clinical: 1Submitted: 1Emergency Use Authorization: 1In Development: 1Clinical Studies: 1BLA Filed: 1Oncology Program: 1BLA Submitted: 1Commercial/IVD Development: 1Commercial (IVD): 1Phase 2 (IND Active): 1Phase 2 Ready: 1Pre-clinical / Clinical: 1Phase 3 (likely): 1Phase 1/Phase 2 (implied): 1Marketed (EUA): 1Service: 1Clinical-stage: 1Pre-clinical/Discovery: 1Pivotal Trial: 1Investigational: 1Phase 1/2a: 1Pre-clinical/Development: 1Advanced Development: 1Platform: 1Research Use Only: 1Early Discovery: 1Preclinical Research: 1Preclinical/Translational: 1Clinical Research: 1All Phases: 1
DrugCompanyIndicationPhase
Tirzepatide (Mounjaro)Eli LillyType 2 DiabetesApproved
Tirzepatide (Zepbound)Eli LillyObesityApproved
DonanemabEli LillyAlzheimer's DiseasePhase 3
MirikizumabEli LillyUlcerative ColitisPhase 3
LebrikizumabEli LillyAtopic DermatitisPhase 3
OrforglipronEli LillyType 2 DiabetesPhase 3
PirtobrutinibEli LillyB-cell MalignanciesPhase 3
RetifanlimabEli LillyVarious CancersPhase 2/3
Verzenio (abemaciclib)Eli LillyBreast CancerApproved
Jardiance (empagliflozin)Eli LillyDiabetes/Heart FailureApproved
Trulicity (dulaglutide)Eli LillyType 2 DiabetesApproved
Taltz (ixekizumab)Eli LillyPsoriasisApproved
Emgality (galcanezumab)Eli LillyMigraineApproved
Tagrisso (osimertinib)AstraZenecaEGFR-mutated lung cancerApproved
Imfinzi (durvalumab)AstraZenecaVarious cancersApproved
Lynparza (olaparib)AstraZenecaBRCA-mutated cancersApproved
Calquence (acalabrutinib)AstraZenecaBlood cancersApproved
Farxiga (dapagliflozin)AstraZenecaDiabetes/Heart failure/CKDApproved
Brilinta (ticagrelor)AstraZenecaCardiovascular diseaseApproved
SymbicortAstraZenecaAsthma/COPDApproved
BreztriAstraZenecaCOPDApproved
ForxigaAstraZenecaType 2 diabetesApproved
Crestor (rosuvastatin)AstraZenecaHigh cholesterolApproved
Cosentyx®NovartisPediatric Hidradenitis Suppurativa (12+)Approved
Pan-mutant-selective PI3Kα inhibitorNovartisBreast CancerAcquisition
Stelara (ustekinumab)Johnson & JohnsonPsoriasis, Crohn's Disease, Ulcerative ColitisApproved
Darzalex (daratumumab)Johnson & JohnsonMultiple MyelomaApproved
Imbruvica (ibrutinib)Johnson & JohnsonBlood CancersApproved
Tremfya (guselkumab)Johnson & JohnsonPsoriasis, Psoriatic ArthritisApproved
Erleada (apalutamide)Johnson & JohnsonProstate CancerApproved
JNJ-4528 (CAR-T)Johnson & JohnsonMultiple MyelomaPhase 3
JNJ-6372Johnson & JohnsonLung CancerPhase 2
NipocalimabJohnson & JohnsonMyasthenia GravisPhase 3
JNJ-1802Johnson & JohnsonTreatment-Resistant DepressionPhase 2
Comirnaty (COVID-19 Vaccine)PfizerSARS-CoV-2 PreventionApproved
PaxlovidPfizerCOVID-19 TreatmentApproved
ElrexfioPfizerMultiple MyelomaApproved
AbrysvoPfizerRSV PreventionApproved
Obesity Pipeline ProgramsPfizerWeight ManagementPhase 2/3
Oncology PortfolioPfizerVarious CancersPhase 1-3
Type 2 Diabetes TherapiesPfizerDiabetes ManagementPhase 2/3
Cardiovascular TreatmentsPfizerHeart DiseasePhase 2/3
Inflammation & Immunology ProgramsPfizerAutoimmune DiseasesPhase 2/3
Opdivo (nivolumab)Bristol Myers SquibbMultiple cancer typesCommercial
Yervoy (ipilimumab)Bristol Myers SquibbMelanoma and other cancersCommercial
Revlimid (lenalidomide)Bristol Myers SquibbMultiple myelomaCommercial
Eliquis (apixaban)Bristol Myers SquibbAtrial fibrillationCommercial
Sprycel (dasatinib)Bristol Myers SquibbCML, ALLCommercial
Breyanzi (lisocabtagene)Bristol Myers SquibbB-cell lymphomasCommercial
Abecma (idecabtagene)Bristol Myers SquibbMultiple myelomaCommercial